Clinical trials: Peptide Receptor Radionuclide Therapy (PRRT)
DLBCL, MCL
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
This is a prospective, single arm,single centre open-label, phase II study in relapsed or refractory DLBCL and MCL non-Hodgkin's lymphoma (NHL), not suitable to other therapies, included HDCT, or patients relapsed after high-dose…
- Conditions
- DLBCL, MCL, Recurrent Disease
- Trial name
- itTRIOlym (NCT02488512)
- Testing
- 90Y-DOTATOC
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Refractory Meningioma
Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction
Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by 177Lutetium-DOTATATE might contribute to improve follow-up and treatment response of refractory meningiomas.
- Trial name
- 177Lumen (NCT05537675)
- Testing
- To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Central Hospital, Nancy, France
Metastatic Nasopharyngeal Cancer
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are avid on 68Ga-DOTATATE imaging will be eligible to…
- Trial name
- SG-AAA-II-01 (NCT05198479)
- Testing
- 77 Lu-DOTA0-Tyr3-Octreotate
- Where
- 2 sites in Singapore
- Volunteers
- 25 people
- Sponsor
- National Cancer Centre, Singapore
Neuroendocrine Tumors
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic…
- Trial name
- PARLuNET (NCT05053854)
- Testing
- Talazoparib
- Where
- Australia
- Volunteers
- 24 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Neuroblastoma
A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
This study is a multicenter, open label phase I dose escalation trial designed to define the Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE in children with refractory or recurrent neuroblastoma.
- Trial name
- NEUROBLU 02 (NCT03966651)
- Testing
- PRRT with 177Lu-DOTATATE
- Where
- 14 sites in France
- Volunteers
- 1 people
- Sponsor
- Institut Claudius Regaud
Neuroendocrine Tumor
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment.
- Trial name
- NCT03197012
- Testing
- 90Y-DOTA-TOC, 68Ga-DOTA-TOC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Hope
Pancreatic Neuroendocrine Tumor
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to be slow growing and are often diagnosed when metastatic.
- Trial name
- NeoNet (NCT05568017)
- Testing
- peptide receptor radionuclide therapy with Y-90-DOTATOC
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- European Institute of Oncology
Gastro-enteropancreatic Neuroendocrine Tumor
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
- Trial name
- LUNET-2 (NCT07653126)
- Where
- 7 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.
- Trial name
- NCT03724409
- Testing
- [90]Y-DOTATOC
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sandeep Laroia
Neuroendocrine Tumors
Best Therapy for Patients With Neuroendocrine Tumors
A prospective observational study containing three arms comprising different therapeutic measures to treat patients with neuroendocrine tumors in advanced stages.
- Trial name
- BESTTHERAPYNET (NCT00815620)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Zentralklinik Bad Berka
Neuroendocrine Tumors, Meningioma
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03273712
- Testing
- 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Neuroendocrine Tumors, Pheochromocytoma
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.
- Conditions
- Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NCT03923257
- Testing
- 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT)
- Where
- United States
- Sponsor
- Sue O'Dorisio
Neuroendocrine Tumors
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
The main goal of the study is to expand cancer preclinical research results on the usefulness of SSTR2-Antagonist [99mTc]Tc-TECANT1 in clinical practice.
- Trial name
- TECANT (NCT05871320)
- Testing
- [99mTc]Tc-TECANT1
- Where
- 3 sites in Austria, Poland and 1 more
- Volunteers
- 10 people
- Sponsor
- Jagiellonian University
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT)
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)
The rationale behind the purpose of this study lays on: the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable…
- Trial name
- FENET-2016 (NCT04790708)
- Testing
- Lutetium-177 (177Lu)-DOTATOC, Yttrium-90 (90Y)-DOTATOC, 177Lu-DOTATOC + 90Y-DOTATOC
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University Hospital of Ferrara
Neuroendocrine Tumors
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers
- Trial name
- NCT04622631
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Dr. Nayruz Knaana
Meningioma
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™
The primary purpose of this study is to investigate the safety and tolerability of a single dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with meningioma.
- Trial name
- NCT03936426
- Testing
- Cu-64 SARTATE and Cu-67 SARTATE
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Neuroendocrine Tumors, Carcinoid Tumor
Personalized PRRT of Neuroendocrine Tumors
In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor, Carcinoma, Neuroendocrine
- Trial name
- P-PRRT (NCT02754297)
- Testing
- 177Lu-Octreotate
- Where
- Canada
- Volunteers
- 275 people
- Sponsor
- CHU de Quebec-Universite Laval
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neuroendocrine Tumors, Quality of Life
HRQoL During PRRT in Patients With NETs
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which may affect the patients' health-related quality of life (HRQoL).
- Conditions
- Neuroendocrine Tumors, Quality of Life, Peptide Receptor Radionuclide Therapy
- Trial name
- NCT05427032
- Volunteers
- 756 people
- Sponsor
- Uppsala University